Hypothalamic-pituitary-ovarian function in menstruating women with Turner syndrome (45,X).
The hypothalamic-pituitary-ovarian hormone secretion patterns were evaluated in two women with 45,X Turner syndrome, spontaneous sexual development, and monthly menstrual periods. Each women had serum gonadotropin and sex steroid determinations during two or more menstrual cycles. During the follicular phase of a menstrual cycle, both women received 100 micrograms gonadotropin-releasing hormone (GnRH) s.c., and serum LH and FSH responses were determined. In addition, one woman collected daily overnight urine specimens for 40 consecutive days, spanning two menstrual periods, for the measurement of LH, FSH, estriol, and free progesterone. The randomly measured hormone results showed low serum progesterone concentrations during luteal phases, consistent with the interpretation of anovulation or inadequate corpus luteum function. At the time of the GnRH stimulation tests, baseline serum FSH concentrations and FSH responses to GnRH were within normal limits, whereas baseline LH levels and LH responses to GnRH were low. The pituitary gonadotropin secretion patterns were more consistent with patterns seen during early puberty than in the perimenopausal state. This interpretation was further confirmed by the urinary excretion patterns of gonadotropins, which were not significantly elevated. Furthermore, the urinary hormone profiles revealed that, although the intermenstrual period was of normal length, the follicular phase was prolonged, with normal levels of LH, FSH, and estriol excreted. The menstrual cycle studied was ovulatory but had a short luteal phase. The hormone results indicated that the dysgenetic ovary of women with 45,X Turner syndrome is capable of producing sufficient quantities of sex steroids and other regulatory factors to maintain gonadotropin secretion patterns that are reminiscent of early puberty.(ABSTRACT TRUNCATED AT 250 WORDS)
Page
L A
LA
Division of Pediatric and Adolescent Endocrinology, Maine Medical Center, Portland.
Beauregard
L J
LJ
Bode
H H
HH
Beitins
I Z
IZ
D000293:Adolescent; D004958:Estradiol / Q000097:blood; D005260:Female; D012739:Gonadal Steroid Hormones / Q000652:urine; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage; D006062:Gonadotropins / Q000097:blood / Q000652:urine; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000503:physiopathology; D008183:Luteal Phase / Q000502:physiology; D008598:Menstruation / Q000502:physiology*; D010053:Ovary / Q000503:physiopathology; D014424:Turner Syndrome / Q000503:physiopathology*
D012739:Gonadal Steroid Hormones; D006062:Gonadotropins; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol